Mersana Therapeutics Inc MRSN
$29.08 $0.04 (0.14%) 1D
Last Updated: Jan 05, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
MRSN Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Mersana Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Mersana Therapeutics Inc. Stock Analysis MRSN
United States Health Care Micro Cap Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. The company is headquartered in Cambridge, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2017-06-28. The company has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The firm's pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).
Mersana Therapeutics Inc (MRSN) Chart
Financial Metrics & Statements of Mersana Therapeutics Inc (MRSN)
FAQ's for Mersana Therapeutics Inc (MRSN)
- As of August 2026, Mersana Therapeutics Inc MRSN is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Mersana Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Mersana Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Mersana Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Mersana Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Mersana Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Mersana Therapeutics Inc (MRSN)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
